Table 1.
Group, route, method, dose, and dose delivered for immunogenicity studies.
| Group | Route | Method | Dose | Dose Delivered |
|---|---|---|---|---|
| 1 | Intramuscular | Intramuscular Needle/syringe |
70 μg HPV VLPs with aluminium adjuvant | 70 μg |
| 2 | Intradermal | Nanopatch™ | 70 μg loaded on Nanopatch™ | 14 μg* |
| 3 | Intradermal | Nanopatch™ | 140 μg with two 70 μg Nanopatches™ | 28 μg* |
| 4 | Intradermal | Mantoux Needle/Syringe |
70 μg | 70 μg |
| 5 | Intradermal | Mantoux Needle/Syringe |
14 μg | 14 μg |
*
Note: Delivery efficiency was at worst-case 20% (i.e. 70 μg/Nanopatch™ X 0.20 = 14 μg), and % of potent HPV VLPs were recovered from the Nanopatch™ following elution under in vitro laboratory conditions.